Ashland Sees Fiscal Q4 Sales Of $530M-$540M And Adjusted EBITDA Of $130M-$140M; FY Sales Projected At $2.1B With Adjusted EBITDA Of $465M-$475M; Continues Reducing Inventory And Lower Value Business Exposure; Significant Year-Over-Year Margin Improvement Expected; Anticipates Mid-Single-Digit Volume Growth In Q4, Offset By Low-Single-Digit Pricing Declines
Portfolio Pulse from Benzinga Newsdesk
Ashland projects fiscal Q4 sales of $530M-$540M and adjusted EBITDA of $130M-$140M. FY sales are projected at $2.1B with adjusted EBITDA of $465M-$475M. The company is reducing inventory and lower value business exposure, expecting significant year-over-year margin improvement. Ashland anticipates mid-single-digit volume growth in Q4, offset by low-single-digit pricing declines. Additionally, Ashland plans to sell its nutraceuticals business to Turnspire Capital and is preparing for a choppy demand environment while advancing long-term growth strategies.
August 06, 2024 | 9:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ashland projects strong fiscal Q4 and FY sales and EBITDA, with significant margin improvement expected. The company is selling its nutraceuticals business to Turnspire Capital and is preparing for a choppy demand environment while advancing long-term growth strategies.
Ashland's strong financial projections for Q4 and FY, along with the sale of its nutraceuticals business, indicate a positive outlook. The company's focus on reducing inventory and lower value business exposure, coupled with expected margin improvements, suggests a favorable short-term impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100